<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>63-ANTIPARKINSONIAN-DOPAMINERGICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPARKINSONIAN DOPAMINERGICS" code="N04B-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or aggravate the psychotic disorders. When a treatment with neuroleptics is necessary for a Parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of &quot;neuroleptic malignant syndrome&quot; (NMS)).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
